The use of statins is discussed in the context of asymptomatic cholesterol bodies. Access to statins as cholesterol-lowering drugs is examined as a biopolitical issue from a science studies’ perspective. From the invention of cholesterol to the medications used in treating it, we try to trace and document the process linking science, pharmaceuticals and politics. We describe Western forms of pharmaceutical inclusion comparing the use of global “wonderdrugs” in the US, the UK and France.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados